PPARG and metabolic syndrome: Taguchi et al. (2011) emphasized that particular angiotensin II receptor blockers (ARBs), such as losartan, act as partial agonists for the peroxisome proliferators activated receptor (PPAR)-γ, thereby influencing lipid metabolism and providing promising outcomes for hypertensive patients with metabolic risk factors like dyslipidemia.